北京先声祥瑞

Beijing Simcere Xiangrui Pharmaceutical Technology is a specialized research and development subsidiary of Simcere Pharmaceutical Group, a prominent innovation-led pharmaceutical company based in China. The company focuses on the discovery and clinical development of novel therapeutics across four core areas: oncology, central nervous system disorders, autoimmune diseases, and anti-infectives. As a key component of Simcere's R&D infrastructure, the Beijing-based entity facilitates the advancement of both internally developed candidates and strategically licensed global assets. Its portfolio includes high-impact treatments such as Sanbexin for stroke and various oncology biologics. The company is committed to leveraging its integrated platform to address significant unmet medical needs in the Chinese and global markets.